283P - Treatment outcomes and toxicity of sunitinib in advanced renal cell carcinoma patients

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer agents
Renal Cell Cancer
Presenter namies Saied
Authors N.M. Saied, Z.M. Abdelhafeez, M.M. Ezz Eldin, N.A. Mosalam
  • Oncology, Ain Shams University Faculty of Medicine, 11315 - Cairo/EG

Abstract

Background

Between November 2012 till December 2014, 30 patients with histologically confirmed advanced RCC were treated with sunitinib at Ain shams clinical oncology department. Medical records were retrospectively reviewed for clinicopathologic characteristics such as age, sex, histology, Eastern Cooperative Oncology Group (ECOG) performance statussites of metastasis, laboratory findings, tumor progression and patient survival. Any Eastern Cooperative Oncology Group (ECOG) performance status were permitted.both treatment schedule were included. Each patient was classified according to the Memorial Sloan–Kettering Cancer Center (MSKCC) risk scoring system .

Methods

Patients 25 years received oral sunitinib 50 mg per day on a 4-weeks-on–2-weeks-off schedule or on 2weeks on 1 week off schedule . Safety was assessed regularly. Tumour measurements were scheduled per local practice.

Results

A total of 30 patients received sunitinib. Median treatment duration and follow-up were 8 and 13 months. Objective response rate was 34%. Median progression-free survival (PFS) and overall survival (OS) were 9 months and 11months . Median PFS in subgroups of interest: aged 60 years (20%), 8 months; compared to 10 months in age group ≤60 years. Eastern Cooperative Oncology Group performance status 0 or 1 (80%), 10 months;compared to 5.5 months in patients with ECOG 2 or 3. LN metastases (40%), 11 months and 8 months in patients with no LN metastasis. The most common grade 3/4 treatment-related adverse events were fatigue (13%), hand and foot syndrome, and anemia (each7%), diarrhea and nausea (each 3%).

Conclusions

Final analysis of the sunitinib reterospective study provided a good opportunity to evaluate the long-term side effects of a tyrosine kinase inhibitor used worldwide in mRCC. Efficacy and safety findings were consistent with previous results.

Clinical trial indentification